High Throughput Screening - Market Research

High Throughput Screening (HTS) is a drug-discovery process widely used in the pharmaceutical industry. It leverages automation to quickly assay the biological or biochemical activity of a large number of drug-like compounds. The process by which thousands of compounds that possess the potential of emerging as a new drug are tested using automated machines.

The main objective of carrying out HTS is to remove the inactive compounds at the initial stage and accumulate the active compounds called hits. These hits are then put through various tests to obtain the leads. The process of HTS when employed on half a million compounds, for example, would provide 300 - 400 hits and this in turn would create 3 to 4 Leads. Ultra High Throughput Screening (uHTS) can be carried out in cell based assays under various physiological environments. This finds application in screening of libraries, holding compounds in millions. Due to various structural effects the primary hits are to be carefully evaluated. When counter screening is employed in cell assays with orthogonal structure, the false positives can be eliminated with ease. Varied read out expertise and cellular setting are utilized during the development of assays. When all these assays gets adapted to the 1536 microtiter plate, the process of counter screening at initial step of hit detection process can be accomplished. Thus early hit detection and lead profiling can be achieved.

High Content Screening (HCS) is the latest drug discovery process that makes use of living cells for drug discovery. It is a highly sophisticated method that attempts to derive maximum information from a single experiment. It uses the information provided by modern cell biology. The use of refined high-resolution microscopes and robots as auto handlers facilitates efficient information retrieval. The analysis of information and the screening process are fully automated, which is an exception as compared to other life sciences technologies.

Strategic partnerships between pharmaceutical and biotechnology companies are the order of the day, and the trend is increasing globally. Another significant trend is the growing alliances between Pharma and Biotech companies and information technology companies such as Microsoft, IBM, Oracle, Sun, and Infosys, etc. The computer platforms generated by such companies help in managing and analyzing the huge amounts of data produced through High Throughput Screening (HTS) and other computational techniques. Effective R&D strategy involves efficient data management and implementation plans. The new technologies promise improved efficacy, decreased toxicity in patients, and reduced time frames and expenditures.

Changing business paradigms brought in by globalization and liberalization are making pharmaceutical companies change strategies for sustenance and growth. Many companies are venturing into HTS studies instead of going for alliances, to become self-sufficient and reduce costs. The R&D wings are increasingly becoming target oriented to face the numerous challenges posed in the drug discovery and development industry.

Global High through put screening market is especially driven by the advancements in HTS technologies and the increasing usage of innovative techniques such as Bioinformatics and Lab-on-a-Chip/Microfluidics. The success of Human Genome Project and latest findings in genomics and proteomics are creating an enormous market for HTS by identifying huge number of drug targets. Currently, automation in High through put screening Market industry is in high gear. The companies are investing heavily in laboratory automation products such as HTS software, database systems, robotics arms and robot based workstations.

Global HTS market is projected to grow at a high rate of 11.86% compounded annually from 2005 through 2020.Global HTS market growth is especially driven by the advancements in HTS technologies and the increasing usage of innovative techniques such as Bioinformatics and Lab-on-a-Chip/Microfluidics. The success of Human Genome Project and latest findings in genomics and proteomics are creating an enormous market for HTS by identifying huge number of drug targets. Currently, automation in HTS industry is in high gear. The companies are investing heavily in laboratory automation products such as HTS software, database systems, robotics arms and robot based workstations. Strategic partnerships between pharmaceutical and biotechnology companies are the order of the day, and the trend is increasing globally. Another significant trend is the alliances between Pharma and Biotech companies and information technology companies such as Microsoft, IBM, Oracle, Sun, and Infosys, etc.

The computer platforms generated by such companies help in managing and analyzing the huge amounts of data produced through High Throughput Screening (HTS) and other computational techniques. Effective R&D strategy involves efficient data management and implementation plans. The new technologies promise improved efficacy, decreased toxicity in patients, and reduced time frames and expenditures. Changing business paradigms brought in by globalization and liberalization are making pharmaceutical companies change strategies for sustenance and growth. Many companies are venturing into HTS studies instead of going for alliances, to become self-sufficient and reduce costs. The R&D wings are increasingly becoming target oriented to face the numerous challenges posed in the drug discovery and development industry. High Throughput Screening report is an ideal research tool providing strategic business intelligence to the corporate sector.

Read Full TOC: https://wiseguyreports.com/reports/high-throughput-screening-market-research-report